Follow The Filings

TMO Thermo Fisher Scientific

Health Care, filed as THERMO FISHER SCIENTIFIC INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 13 managers in 2026 Q2, sold by 4

  • 4 Owners
  • #16
  • Max 1.4%
  • Master 0.27%
  • $152M
  • 1 new 1 add 1 reduce

In 2026 Q3 John Armitage opened a position in Thermo Fisher Scientific, Murphy Pohlad added, and David Katz trimmed.

Who owns this now

Largest portfolio weights among holders, up to 1.4% (John Armitage, Egerton Capital (UK)). Not free-float ownership.

  1. John Armitage New 1.4%
  2. David Katz Reduce 1.3%
  3. Murphy Pohlad Add 0.56%
  4. Kentucky Trust Co. 0.01%

Who owns TMO

Sorted by value, long equity only, as of 2026 Q3.

History
John Armitage, Egerton Capital (UK) 1.4% New 1.4% 198,227 $134M History
David Katz, Matrix Asset Advisors 1.3% Reduce −13.4% 23,947 $16M History
Murphy Pohlad, Murphy Pohlad Asset Management 0.56%, was 0.41% Add +1.5% 2,402 $1.6M History
Kentucky Trust Co., Kentucky Trust 0.01% Hold 16 $11K History

4 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TMO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TMO insider trades
  • None no insider bought on the open market
  • $68.4M sold by 3 insiders outside a trading plan
  • $75.6M sold by 4 insiders under 10b5-1 plans
  1. Gianluca Pettiti COO
    Planned sale
    $2.5M 4,133 shares at $614.38 15% of stake
    Traded Aug 31 Filed Sep 1
    ↗
  2. Marc N Casper CEO
    Planned sale
    $172K 275 shares at $627.05 0.2% of stake
    Traded Aug 24 Filed Aug 26
    ↗
  3. Marc N Casper CEO
    Planned sale
    $12.6M 20,000 shares at $628.09 14% of stake
    Traded Aug 20–21 Filed Aug 24
    ↗
  4. Lisa P. Britt Sr. VP and Chief HR Officer
    Sale
    $7M 11,440 shares at $613.12 44% of stake
    Traded Aug 19 Filed Aug 20
    ↗
  5. Michael D Shafer Executive Vice President
    Planned sale
    $15.3M 25,500 shares at $600.00 55% of stake
    Traded Aug 11 Filed Aug 13
    ↗
  6. Joseph R. Holmes VP & Chief Accounting Officer
    Sale
    $246K 420 shares at $584.81 12% of stake
    Traded Aug 7 Filed Aug 10
    ↗
  7. Marc N Casper CEO
    Planned sale
    $2.9M 4,883 shares at $586.12
    Traded Aug 7 Filed Aug 10
    ↗
  8. Marc N Casper CEO
    Planned sale
    $8.6M 15,000 shares at $574.46
    Traded Aug 6 Filed Aug 7
    ↗
  9. Marc N Casper CEO
    Planned sale
    $8.6M 15,000 shares at $575.23
    Traded Aug 5 Filed Aug 7
    ↗
  10. Lisa P. Britt Sr. VP and Chief HR Officer
    Sale
    $3.4M 5,850 shares at $580.00 28% of stake
    Traded Aug 6 Filed Aug 7
    ↗
  11. Gianluca Pettiti COO
    Planned sale
    $226K 400 shares at $565.00 1.6% of stake
    Traded Jul 27 Filed Jul 28
    ↗
  12. Gianluca Pettiti COO
    Planned sale
    $185K 400 shares at $462.66 1.6% of stake
    Traded Apr 27 Filed Apr 29
    ↗
  13. Michael D Shafer Executive Vice President
    Planned sale
    $803K 1,607 shares at $499.40 7.1% of stake
    Traded Mar 11 Filed Mar 12
    ↗
  14. Marc N Casper CEO
    Planned sale
    $2.1M 4,000 shares at $514.82 3.1% of stake
    Traded Mar 5 Filed Mar 9
    ↗
  15. Marc N Casper CEO
    Planned sale
    $5.1M 10,000 shares at $507.75 7.5% of stake
    Traded Mar 3–4 Filed Mar 5
    ↗

Also filed in the last 12 months, not counted as buying or selling: 47 share withholdings for taxes, 27 option exercises, 24 stock grants, and 2 gifts.

Congress

20 members of Congress traded TMO in the last three years: 14 buys and 27 sales. 19 members listed it in 2025 annual reports.

All Congress trades
  1. Michael A. Rulli R-OH-6 Sell $1K–$15K Dec 12, 2024 filed Aug 7
  2. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  3. Dan Newhouse R-WA-4Spouse Sell $1K–$15K Jul 10 filed Jul 17
  4. Dwight Evans D-PA-3 Partial sale $1K–$15K May 7 filed May 15
  5. Julia Letlow R-LA-5 Buy $1K–$15K Jul 25, 2025 filed Jan 13
  6. Julia Letlow R-LA-5 Sell $1K–$15K Apr 28, 2025 filed Jan 13

SEC filings

Recent issuer filings from EDGAR, 4 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.07 Filing Doc

Source: SEC EDGAR submissions, updated 7 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $42.86B $42.88B $44.56B
Net income — — $6.7B
Net margin * — — 15.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $24.59B $22.14B $28.71B
Total non-current assets * $74.14B $75.18B $81.64B
Total assets $98.73B $97.32B $110.34B
Total current liabilities $14.01B $13.33B $15.19B
Total equity $46.74B $49.58B $53.41B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $8.41B $8.67B $7.82B
Cash from investing -$5.14B -$5.84B -$4.05B
Cash from financing -$3.62B -$6.79B $1.8B
Net change in cash -$0.44B -$4.06B $5.84B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.